May 15, 2020 / 6:57 PM / 2 months ago

Clovis Oncology's Rubraca gets U.S. FDA approval for prostate cancer

May 15 (Reuters) - Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with castration-resistant prostate cancer, whose tumors have a genetic mutation. The approval is for the drug’s use in patients whose tumors have a mutation called BRCA, and whose disease had advanced despite prior rounds of chemotherapy, the company said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below